GlaxoSmithKline chooses not to exercise right to MET/RET/VEGFR2 inhibitor XL184

GlaxoSmithKline has decided not to exercise its option to license MET/RET/VEGFR2 inhibitor from Exelixis

Exelixis MET/VEGFR2/RET inhibitor XL184 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis MET/VEGFR2/RET inhbitor XL184 demonstrates a 55% Response Rate and 84% Disease Control Rate in Patients with Medullary Thyroid Cancer

ImClone initiate Phase II trial of IMC-1121B in ovarian cancer

ImClone have initiated a phase II clinical trial of VEGFR-2 MAb IMC-1121B in patients with advanced ovarian cancer.

Vandetanib effective in xenograft models of sarcoma

AstraZeneca’s VEGFR2/EGFR inhibitor has shown activity against sarcoma cell lines in xenograft models

Eisais Multi-Kinase VEGFR Inhibitor E7080 effective in animal models

Eisai’s Multikinase VEGFR Inhibitor E7080 has been shown to be effective in a mammary fat pad xenograft model of human breast cancer using MDA-MB-231

AVEO initiate Phase Ib trial with VEGFR inhibitor AV-951

AVEO Pharmaceuticals has initiated a Phase Ib clinical study its  VEGFR 1/2/3 receptor inhibitor AV-951.

ImClone initate Phase II trial in prostate cancer comparing IMC-A12 and IMC-1121B

ImClone have commenced enrollment in a Phase II trial with either IMC-A12 or IMC-1121B in patients with advanced prostate cancer. IMC-A12 is a fully human, IgG1 anti-IGF-1 receptor (IGF-1R) monoclonal antibody and IMC-1121B is its fully human, IgG1 anti-vascular growth factor receptor-2 (VEGFR-2) monoclonal antibody.

J&J publish series of dual Aurora-A/VEGF-R2 kinase inhibitors

J&J have published a series of 7-[1H-indol-2-yl]-2,3-dihydro-isoindol-1-one dual Aurora-A/VEGF-R2 kinase inhibitors.

ImClone initiate Phase III for Anti-VEGFR2 MAb IMC-1121B in Breast Cancer

ImClone Systems have initiated a global Phase 3 clinical trial of VEGFR2 MAb IMC-1121B in women with metastatic breast cancer.

J&J publish series of Aurora A/VEGFR-1 inhibitors

J&J have published a series of Aurora A/VEGFR-2 inhibitors